The University of Texas MD Anderson Cancer Center and UnitedHealthcare have launched a pilot to explore a new cancer care payment model for head and neck cancers that focuses on quality patient care and outcomes.
The Food and Drug Administration’s (FDA) approval of a new vaccine that targets five additional strains of human papilloma virus (HPV) fortifies a proven cancer-prevention weapon, according to Ronald A. DePinho, M.D., president of The University of Texas MD Anderson Cancer Center.
MD Anderson study finds no association with assay and decreased chemotherapy use in older patients.
Children who are having difficulty processing trauma or loss can now turn to the Trauma and Grief Center for Youth at The University of Texas Health Science Center at Houston (UTHealth).
To assist children and families struggling with pediatric bipolar disorder, the Pediatric Bipolar Inpatient Unit opened today at The University of Texas Harris County Psychiatric Center.
A study that investigated the potential of the compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.
The University of Texas Health Science Center at Houston (UTHealth) School of Biomedical Informatics has been awarded grants totaling $7.3 million to enhance health care and biomedical discovery through the use of health information techno
Study results of CD19-directed chimeric antigen receptor (CAR) therapy using the Sleeping Beauty non-viral transduction system to modify T cells has demonstrated further promise in patients with advanced hematologic malignancies.
A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it is among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.
A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia.
Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.
Young Puerto Rican women and their mothers know little about the human papillomavirus (HPV) and cervical cancer, according to researchers at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health.
Peter Friedl, M.D., Ph.D., professor of genitourinary medical oncology at The University of Texas MD Anderson Cancer Center, has received one of Italy’s top scientific awards for his work in imaging and cancer growth, metastasis and therapy response.
Their responsibilities may range from exploring the intricacies of biostatistics to bringing new drugs more rapidly to the patient, but eight faculty members from The University of Texas MD Anderson Cancer Center all share one honor – being named as Fellows by the American Association for the Advancement of Science.
Overindulging at a holiday party or two this season isn’t going make a big difference in someone’s health. But it could be a much different story for people with type 2 diabetes.
A protein kinase or enzyme known as PKM2 has proven to control cell division, potentially providing a molecular basis for tumor diagnosis and treatment.
Veronica Garcia, a student at The University of Texas Graduate School of Biomedical Sciences at Houston, has been awarded a Robert D. Watkins Graduate Research Fellowship from the American Society for Microbiology.
It’s hard to believe, but there are similarities between bean sprouts and human cancer.
Researchers at The University of Texas Health Science Center at Houston (UTHealth) have received a $1.6 million grant for a preclinical study investigating whether a probiotic might be helpful in preventing a life-threatening condition in pre-term infants called necrotizing enterocolitis (NEC).
Scientists have found that altering members of the p53 gene family, known as tumor suppressor genes, causes rapid regression of tumors that are deficient in or totally missing p53.
Offering small financial incentives doubles smoking cessation rates among socioeconomically disadvantaged smokers, according to research from The University of Texas Health Science Center at Houston (UTHealth).
Molecules called long non-coding RNAs (lncRNAs) have been implicated in breast cancer but exactly why they cause metastasis and tumor growth has been little understood…until now.
Testosterone replacement therapy has become fashionable and many men are blindly taking it in a quest for more energy and a better sex life and are not looking at one potential danger....heart attack.
Bruce Kone, M.D., professor in the Division of Renal Diseases and Hypertension at The University of Texas Health Science Center at Houston (UTHealth), has been named chairman of a Scientific Review Group (SRG) that evaluates training grant and career development award applications for the National Institutes of Health (NIH). It is called the Kidney, Urologic and Hematologic Diseases SRG.
Houston, Texas -- For his myriad clinical, organizational and scientific accomplishments in the field of gynecologic oncology and the health and well-being of women, David M. Gershenson, M.D. has been recognized with the International Gynecology Cancer Society’s (IGCS) Award of Excellence.
By transforming human scar cells into blood vessel cells, scientists may have discovered a new way to repair damaged tissue. The method, described in an upcoming issue of Circulation (early online), appeared to improve blood flow, oxygenation, and nutrition to areas in need.
On Thanksgiving Day, good eating habits spiral out of control and exercise plans are thrown out the window resulting in undesired weight gain.
November 5, 2014 – In the next 15 years, more than one in 10 colon cancers and nearly one in four rectal cancers will be diagnosed in patients younger than the traditional screening age, according to researchers at The University of Texas MD Anderson Cancer Center.
A 93-year old U.S. Veteran who survived World War II, and the Korean and Vietnam Wars battled severe aortic stenosis and won after receiving a Trans-catheter Aortic Valve Replacement (TAVR). Would make nice Veterans Day feature.
In terms of duration of treatment and cost, patients with early stage breast cancer may benefit from accelerated partial breast irradiation (APBI) with proton therapy versus whole breast irradiation (WBI), according to new research from The University of Texas MD Anderson Proton Therapy Center.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right